TELA Bio Inc (NASDAQ: TELA) closed the day trading at $4.69 down -1.26% from the previous closing price of $4.75. On the day, 846217 shares were traded. TELA stock price reached its highest trading level at $4.7800 during the session, while it also had its lowest trading level at $4.6300.
For a better understanding of TELA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.43 and its Current Ratio is at 5.36. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 1.32.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Lake Street on May 31, 2022, initiated with a Buy rating and assigned the stock a target price of $17.
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 14 when KOBLISH ANTONY bought 11,000 shares for $4.54 per share. The transaction valued at 49,976 led to the insider holds 303,634 shares of the business.
Cuca Roberto bought 10,000 shares of TELA for $44,938 on Nov 14. The COO and CFO now owns 62,371 shares after completing the transaction at $4.49 per share. On Apr 21, another insider, ORBIMED ADVISORS LLC, who serves as the 10% Owner of the company, sold 27,700 shares for $9.41 each. As a result, the insider received 260,657 and left with 2,835,542 shares of the company.
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TELA now has a Market Capitalization of 114.85M and an Enterprise Value of 97.36M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.16 while its Price-to-Book (P/B) ratio in mrq is 3.76. Its current Enterprise Value per Revenue stands at 1.83 whereas that against EBITDA is -2.57.
Stock Price History:
Over the past 52 weeks, TELA has reached a high of $13.18, while it has fallen to a 52-week low of $4.23. The 50-Day Moving Average of the stock is 6.6791, while the 200-Day Moving Average is calculated to be 9.2812.
Over the past 3-months, TELA traded about 124.11K shares per day on average, while over the past 10 days, TELA traded about 314.01k shares per day. A total of 19.17M shares are outstanding, with a floating share count of 17.02M. Insiders hold about 30.50% of the company’s shares, while institutions hold 62.62% stake in the company. Shares short for TELA as of Oct 30, 2023 were 735.03k with a Short Ratio of 0.74M, compared to 552.31k on Sep 28, 2023. Therefore, it implies a Short% of Shares Outstanding of 3.00% and a Short% of Float of 4.91%.
Current recommendations for the stock of the company come from 5 analysts. On average, analysts expect EPS of -$0.44 for the current quarter, with a high estimate of -$0.42 and a low estimate of -$0.46, while EPS last year was -$0.52. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.36 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.93 and -$1.99 for the fiscal current year, implying an average EPS of -$1.96. EPS for the following year is -$1.57, with 5 analysts recommending between -$1.41 and -$1.69.
5 analysts predict $16.39M in revenue for the current quarter. It ranges from a high estimate of $16.9M to a low estimate of $15.5M. As of the current estimate, TELA Bio Inc’s year-ago sales were $11.62M, an estimated increase of 41.00% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $16.2M, an increase of 34.80% less than the figure of $41.00% in the same quarter last year. There is a high estimate of $16.6M for the next quarter, whereas the lowest estimate is $15.4M.
A total of 5 analysts have provided revenue estimates for TELA’s current fiscal year. The highest revenue estimate was $58.42M, while the lowest revenue estimate was $57M, resulting in an average revenue estimate of $57.88M. In the same quarter a year ago, actual revenue was $41.42M, up 39.70% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $75.2M in the next fiscal year. The high estimate is $77.91M and the low estimate is $72.7M. The average revenue growth estimate for next year is up 29.90% from the average revenue estimate for this year.